5 Best Immunology Stocks to Invest In
Xencor, Inc.
Celldex Therapeutics Inc. (CLDX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Polar Capital Brian Ashford-Russell And Tim Woolley | 3,059,492 | $128,406,879 | -3% | 0.67% |
| 2. | Kynam Capital Derrick Tang | 2,900,000 | $121,713,000 | -4% | 12.73% |
| 3. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,372,185 | $57,590,604 | +42% | 1.46% |
| 4. | Point72 Asset Management Steve Cohen | 1,283,797 | $53,880,960 | -54% | 0.13% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 898,800 | $37,722,636 | -30% | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $46.28 | 430 | Officer | 430 | 2021-08-11 | Filing | |
| $4.73 | 2,115 | Officer | 2,115 | 2020-06-11 | Filing | |
| $4.83 | 1,050 | Officer | 1,367 | 2020-06-10 | Filing | |
| $3.01 | 1,000 | Officer | 1,000 | 2020-06-09 | Filing | |
| $3.05 | 9,750 | Officer | 10,735 | 2020-06-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $35.42 | 17,172 | 28,125 | 2024-06-14 | Filing | ||
| $34.87 | 30,000 | 9,074 | 2024-06-14 | Filing | ||
| $35.06 | 15,000 | 9,074 | 2024-06-07 | Filing | ||
| $35.26 | 45,000 | 2,115 | 2024-06-07 | Filing | ||
| $33.65 | 58,369 | 13,383 | 2024-06-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,050,409 | $279,619,221 | 0.02% | |
| 2. | 6,476,561 | $256,860,411 | 0.04% | |
| 3. | 3,675,692 | $145,777,945 | 0% | |
| 4. | 3,630,013 | $143,966,316 | 2.34% | |
| 5. | 3,463,201 | $137,350,552 | 2.14% |
News See All
Top 10 Biotech Stocks to Buy According to Jeremy Green's Redmile Group
In this article, we will discuss the top 10 biotech stocks to buy according to Jeremy Green's Redmile Group.
Hedge Funds Are Crazy About Celldex Therapeutics, Inc. (CLDX)
In this article we are going to use hedge fund sentiment as a tool and determine whether Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a good investment right now.
Should I Avoid Celldex Therapeutics, Inc. (CLDX)?
While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors are starting to get cautious...
5 Stocks to Buy According to Neil Shahrestani's Ikarian Capital
In this article, we will discuss the 10 stocks to buy according to Neil Shahrestani's Ikarian Capital.
Where Do Hedge Funds Stand On Celldex Therapeutics, Inc. (CLDX)?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities...
Is CLDX Stock A Buy or Sell?
In this article we will take a look at whether hedge funds think Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a good investment right now.
Hedge Funds Have Never Been This Bullish On Celldex Therapeutics, Inc. (CLDX)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC.
Hedge Funds Are Dumping Celldex Therapeutics, Inc. (CLDX)
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March...
Is Celldex Therapeutics, Inc. (CLDX) A Good Stock To Buy?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.